Vanta Bioscience
19.60
-0.04(-0.20%)
Market Cap₹13.97 Cr
PE Ratio130.93
IndustryHealthcare
Company Performance:
1D-0.20%
1M0.00%
6M-4.85%
1Y0.00%
5Y0.00%
View Company Insightsright
More news about Vanta Bioscience
30Jan 26
Vanta Bioscience Appoints Ms. Pooja Kothari as Company Secretary and Compliance Officer
Vanta Bioscience Limited appointed Ms. Pooja Kothari as Company Secretary and Compliance Officer effective January 30, 2026, following board approval. Ms. Kothari, an ICSI Associate Member with 4 years of experience in Company Law and Secretarial Compliances, brings expertise from working with private and unlisted public companies. The appointment complies with SEBI regulations and strengthens the company's governance framework.
 no imag found
05Sept 25
Vanta Bioscience Faces Insolvency Application Over Unpaid Salary Claims
Vanta Bioscience Limited is facing an insolvency application filed by S Venkata Rao, its former Whole Time Director & CEO, under Section 9 of the Insolvency and Bankruptcy Code, 2016. Rao alleges the company defaulted on salary and interest payments totaling Rs. 1.18 crore. Vanta Bioscience denies all allegations, calling them baseless, and has sought legal advice to protect its interests. The company states it has not received any communications from NCLT regarding this matter.
 no imag found
01Aug 25
Vanta Bioscience Reports Significant Losses for FY2025 Amid Revenue Decline
Vanta Bioscience Limited, a preclinical contract research organization, reported a substantial net loss for FY2025. Standalone net loss was Rs 265.95 lakh, compared to a profit of Rs 5.11 lakh in the previous year. Revenue from operations declined by 86.80% to Rs 112.74 lakh. Consolidated results showed a net loss of Rs 477.49 lakh, with revenue falling by 79.80% to Rs 196.36 lakh. The company faced operational challenges, including delays in consolidating financial results due to late receipt of accounts from an associate company. Despite financial difficulties, total assets increased by 2.52% to Rs 52.90 crore, while current liabilities rose by 39.22% to Rs 14.20 crore.
 no imag found
Vanta Bioscience
19.60
-0.04
(-0.20%)
1 Year Returns:0.00%
Industry Peers
Syngene International
389.50
(-1.54%)
Indegene
598.55
(-0.49%)
Suven Life Sciences
377.30
(-0.19%)
Vimta Labs
640.40
(+0.75%)
Bilcare
100.64
(+5.00%)
TAKE
14.51
(+4.99%)
Adeshwar Meditex
16.30
(0.0%)
Vanta Bioscience
19.60
(-0.20%)